Katy Athersuch
Datos Biográficos
| ID | 9800939 |
|---|---|
| NOMBRE | Katy Athersuch |
| NOMBRES | Katy |
| APELLIDO | Athersuch |
| FIRMA | ATHERSUCH K |
| AFILIACIONES | Médecins Sans Frontières |
| VERIFICADO | No |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 1 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2022 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2022 |
| ÍNDICE H | 0 |
Recently developed drugs for the treatment of drug-resistant tuberculosis
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB treatment. Despite evidence of improved efficacy and reduced toxicity of multidrug regimens including the two agents, access to bedaquiline …
Sin obras prominentes en esta página.
Recently developed drugs for the treatment of drug-resistant tuberculosis
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB treatment. Despite evidence of improved efficacy and reduced toxicity of multidrug regimens including the two agents, access to bedaquiline …
Bedaquiline (1 obra) · Business (1 obra) · Clinical trial (1 obra) · Drug (1 obra) · Drug development (1 obra) · Incentive (1 obra) · Intensive care medicine (1 obra) · Internal Medicine (1 obra) · Medicine (1 obra) · Mycobacterium tuberculosis (1 obra)